shigyakusan

Shigyakusan (also known as Tsumura Japan [TJ]-35) is composed of peony, bitter orange, licorice, and Bupleuri radix is used for cholecystitis and gastritis as an anti-inflammatory agent. We investigated the effect of TJ-35 on alloimmune response in a murine heart transplantation model. CBA mice that underwent transplantation of a C57BL/6 (B6) heart were assigned to four groups: no treatment, TJ-35-exposed, each component-exposed, or each component missing-exposed. The four groups above each received oral administration of TJ-35, each component, or TJ-35 with each component missing from the day of transplantation until 7 days, respectively. Untreated CBA recipients rejected B6 cardiac grafts acutely (median survival time [MST], 7 days). TJ-35-exposed CBA recipients had significantly prolonged B6 allograft survival (MST, 20.5 days). However, MSTs of CBA recipients that had been administered each component and TJ-35 with each component missing did not reach that of TJ-35-exposed recipients. Adoptive transfer of CD4⁺ splenocytes from TJ-35-exposed primary allograft recipients resulted in significant prolonged allograft survival in naïve secondary recipients (MST, 63 days). Flow cytometry studies showed that the percentage of CD4⁺CD25⁺Foxp3⁺ cell population was increased in TJ-35-exposed CBA recipients. In conclusion, TJ-35-induced prolongation of fully allogeneic cardiac allografts and may generate regulatory CD4⁺CD25⁺Foxp3⁺ cells in our model. The effect seemed to require all components of TJ-35.

Shigyakusan is a traditional Japanese herbal (Kampo) medicine used to treat inflammatory conditions such as cholecystitis and gastritis as well as psychiatric disorders. This study examined the anxiolytic-like effect of Shigyakusan extract (SS), and evaluated the activity of the main compound. Three behavioral tests in mice were used to evaluate the activity of SS. Samples were administered orally over a 10-day period. A light and dark box (LDB) test was performed on the 8th day, while an open field (OF) test was done on the 9th day, and an elevated plus maze (EPM) test was performed on the 10th day. Diazepam (DZ), a typical anxiolytic drug, was used as the positive control. Administration of 10 mg/kg DZ resulted in a significant anxiolytic-like effect in the LDB and EPM tests, while administration of 0.3 g/kg SS resulted in a weak anxiolytic-like effect. In the OF test, while DZ caused a significant reduction of locomotor activity, SS did not cause any changes compared to the water controls. This suggests that locomotor activity may be a side effect of DZ, and thus SS, which lacks this response, may be a more useful treatment. Quantitative analysis performed to clarify the activity of the main compound also determined that SS contained 51.4 mg/g naringin, which also has been reported to have anxiolytic-like activity. Since these results suggested that this compound might be responsible for the activity of SS, we subsequently examined the oral administration of a similar dose of naringin. Although we observed a tendency for a weak anxiolytic-like effect, this effect was not greater than that seen for SS.